ADCs are innovative therabees
1. A new class of biopharmaceutical drugs used to treat cancer
2. A more precise anti-tumor targeting
3. A stronger therapeutic effectiveness
4. A better quality of life for patients
They are composed of 3 elements
mAb (Monoclonal AntiBody): Specific protein that recognizes and targets cancer cells
Payload: Highly active ingredient that kills cancer cells
Linker: Small molecule that connects the cytotoxic payload to the mAb
ADCs have potent perspectives
12 ADCs launched
128 ADCs in active clinical development
Do you want to learn more?
Discover our FAQ
